A case report on Myxedema Coma: Is enteral route as good as intravenous levothyroxine in an Indian intensive care setting?
Main Article Content
Abstract
Myxedema coma is a rare life-threatening clinical condition in patients with longstanding severe untreated hypothyroidism, wherein adaptive mechanisms fail to maintain homeostasis. We report a rare case involving a 35-year-old male with an intellectual disability, who arrived at our intensive care unit in a comatose state. Following a thorough examination of numerous potential differential diagnoses, the patient was determined to be suffering from myxedema coma a rare presentation. The patient responded well to tablet levothyroxine administered via a nasogastric tube, achieving the desired positive outcome. Due to the exceptionally low incidence of this condition in our country, we were initially diverted into considering more frequent causes of coma. The coexistence of a pre-existing intellectual disability, coupled with factors like Herpes Zoster infection, hyponatremia, and bradycardia, posed hurdles in promptly diagnosing this condition, which was further complicated by its rarity. This case report describes the management of myxedema coma and depicts the clinical and logistic challenges faced while managing this case. This case also emphasizes the importance of readiness and the ability to adapt treatment to individual circumstances.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Bourcier S, Coutrot M, Ferré A, et al. Critically ill severe hypothyroidism: a retrospective multicenter cohort study. Ann Intensive Care. 2023;13(1):15. Published 2023 Mar 9. doi:10.1186/s13613-023-01112-1
3. Chen DH, Hurtado CR, Chang P, Zakher M, Angell TE. Clinical Features and Outcomes of Myxedema Coma in Patients Hospitalized for Hypothyroidism: Analysis of the United States National Inpatient Sample. Thyroid. 2024;34(4): 419-428. doi:10.1089/thy.2023.0559
4. Ono Y, Ono S, Yasunaga H, Matsui H, Fushimi K, Tanaka Y. Clinical characteristics and outcomes of myxedema coma: Analysis of a national inpatient database in Japan. J Epidemiol. 2017;27(3):117-122. doi:10.1016/j.je.2016.04.002
5. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751. doi:10.1089/thy.2014.0028
6. Wall CR. Myxedema coma: diagnosis and treatment. Am Fam Physician. 2000;62(11):2485-2490.
7. Charoensri S, Sriphrapradang C, Nimitphong H. Split high-dose oral levothyroxine treatment as a successful therapy option in myxedema coma. Clin Case Rep. 2017;5(10):1706-1711. Published 2017 Sep 8. doi:10.1002/ccr3.1131
8. Liu H, Li W, Zhang W, Sun S, Chen C. Levothyroxine: Conventional and Novel Drug Delivery Formulations. Endocr Rev. 2023;44(3): 393-416. doi:10.1210/endrev/bnac030
9. Dutta P, Bhansali A, Masoodi SR, Bhadada S, Sharma N, Rajput R. Predictors of outcome in myxoedema coma: a study from a tertiary care centre. Crit Care. 2008;12(1):R1. doi:10.1186/cc6211
10. Roy N, Majumder A, Sanyal D, Chaudhuri SR, Sarkar S, Pathak A. Legions of Presentations of Myxedema Coma: A Case Series from a Tertiary Hospital in India. J ASEAN Fed Endocr Soc. 2020;35(2):233-237. doi:10.15605/jafes.035.02.12
11. Arlot S, Debussche X, Lalau JD, et al. Myxoedema coma: response of thyroid hormones with oral and intravenous high-dose L-thyroxine treatment. Intensive Care Med. 1991;17(1):16-18. doi:10.1007/BF01708403
12. Rajendran A, Bhavani N, Nair V, Pavithran PV, Menon VU, Kumar H. Oral levothyroxine is an effective option for myxedema coma: a single-centre experience. Eur Thyroid J2021;10:52–58. doi: 10.1159/00050785
13. Gadaen RJ, Tummers-de Lind van Wijngaarden RF. Hypothyroid Crisis: Oral or Intravenous Treatment? A Report of Two Cases. Eur J Case Rep Intern Med. 2021;8(9):002752. Published 2021 Sep 10. doi:10.12890/2021_002752